BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會

講師

Yoshitake Maeda

Session 8 – Unlock Hidden Value of Research in Asia

Date:22 July (Thursday)
Time:  14:00 – 15:30 (GMT+8)

Yoshitake Maeda

Director
Bristol Myers Squibb

Dr. Yoshitake Maeda is currently Director of Business Development (BD), Search & evaluation in Japan and Asia in Bristol Myers Squibb. He has joined BMSKK as director of External Innovation since February 2017. Prior to joining BMSKK, Yoshitake worked at Kyowa Hakko Kirin (KHK) as the manager of BD. Before BD in KHK, he has over 18 years of experience working in R&D at KHK, Kirin Pharma and Kirin Brewery.
.

Speech title & Synopsis

External innovation activities in the Asia region

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We focus on discovering and developing innovative medicines that address serious disease in areas of significant unmet medical need such as oncology, hematology, immunology, cardiovascular, fibrosis, and neuroscience.

Partnering plays a strategic role in executing our R&D strategy, evolving our portfolio and growth. Our goal in partnering is to discover, develop and deliver transformational medicines to patients by bringing innovative science, research and technology together with our capabilities and expertise.

We are actively seeking for partnering opportunities worldwide including Japan, Korea and Taiwan with academia, research institutes and biotechs for drug seeds from early to late stages of development, precision medicine, biomarkers and data analysis.

For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.
.